883 related articles for article (PubMed ID: 20837949)
21. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
[TBL] [Abstract][Full Text] [Related]
22. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
[TBL] [Abstract][Full Text] [Related]
23. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
24. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy.
Cheung WI; Lin SY; Leung VK; Fung KS; Lam YK; Lo FH; Chau TN
Hong Kong Med J; 2011 Oct; 17(5):376-80. PubMed ID: 21979474
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
27. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
28. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
[TBL] [Abstract][Full Text] [Related]
29. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Muñoz Bertrán E; Pérez Ceballos E; Gómez Espín R; Ortega González I
Gastroenterol Hepatol; 2010 May; 33(5):377-81. PubMed ID: 20363054
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
31. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
[TBL] [Abstract][Full Text] [Related]
32. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment.
Kim MG; Park SY; Kim EJ; Kim YM; Kim HY; Lee YK; Zang DY; Kim HJ
Acta Haematol; 2011; 125(3):121-4. PubMed ID: 21150178
[TBL] [Abstract][Full Text] [Related]
34. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.
Faggioli P; De Paschale M; Tocci A; Luoni M; Fava S; De Paoli A; Tosi A; Cassi E
Haematologica; 1997; 82(1):38-42. PubMed ID: 9107080
[TBL] [Abstract][Full Text] [Related]
35. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
[TBL] [Abstract][Full Text] [Related]
36. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
Koo YX; Tan DS; Tan BH; Quek R; Tao M; Lim ST
J Clin Oncol; 2009 May; 27(15):2570-1; author reply 2571-2. PubMed ID: 19364951
[No Abstract] [Full Text] [Related]
37. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
38. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
[TBL] [Abstract][Full Text] [Related]
39. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
40. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.
Pei SN; Chen CH; Lee CM; Wang MC; Ma MC; Hu TH; Kuo CY
Ann Hematol; 2010 Mar; 89(3):255-62. PubMed ID: 19697028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]